Tyrosine kinase inhibitors alone as a first-line treatment for patients with non-small-cell lung cancer harboring mutant epidermal growth factor receptorToshihiko Iuchi, Hironori Ashinuma, Meiji Itakura et al.|Annals of Oncology|2016Cited by 0